Berlin:
German firm BioNTech stated Thursday that patent protection for Covid-19 vaccines is not holding back production or provide of the jabs that it created with Pfizer.
“Patents are not the limiting factor for the production or supply of our vaccine. They would not increase the global production and supply of vaccine doses in the short and middle term,” it told AFP in a statement, in a tacit rejection of a get in touch with from the United States to waive patent protections for Covid vaccines.
Rather it was troubles ranging from the set up of manufacturing web pages to the sourcing of raw components to the availability of certified personnel that had been holding up the procedure.
“If any of these requirements is not met, the quality, safety and efficacy of the vaccine cannot be ensured by the manufacturer nor the innovator. This could put the health of the vaccinees at risk,” warned the business.
Underlining the minute information that could jeopardise production, the Mainz-based business stated that if some of the “limited and important raw materials” are not employed in the most effective manner, it could lead to fewer vaccine doses getting manufactured.
BioNTech stated it has been currently capable to ramp up provide by getting into into licensing and manufacturing partnerships with other pharmaceutical businesses such as Merck, Novartis and Sanofi.
It argued that additional expansion of such cooperation would “help to end this pandemic by ensuring worldwide supply with safe and effective vaccines”.
BioNTech/Pfizer’s vaccine became the initially Covid-19 jab to be authorized for use in the West late last year.
It is now supplying more than 90 nations worldwide, and is expecting to ramp up its production to up to 3 billion doses by the finish of the year from 2.5 billion doses anticipated previously.
The pace will additional accelerate to more than 3 billion doses in 2022.
(This story has not been edited by TheSpuzz employees and is auto-generated from a syndicated feed.)